The COVID-19 cart is still in front of the horse

Following up on my previous posts, regarding PCR tests and vaccines for SARS CoV-2 (Covid-19), the cart is still in front of the horse.  Read the CDC document linked below and see for yourself.  Here are a few quotes excerpted from that CDC document dated July, 2020.  I provided the bolding for emphasis:

From the official CDC Covid-19 method document for the PCR Covid-19 test, with revisions (full citation and link below.)

Page 2

“Results are for the identification of 2019-nCoV RNA. The 2019-nCoV RNA is generally detectable in upper and lower respiratory specimens during infection. Positive results are indicative of active infection with 2019-nCoV but do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.  Negative results do not preclude 2019-nCoV infection and should not be used as the sole basis for treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.”

Page 39

Detection of viral RNA may not indicate the presence of infectious virus or that 2019-nCoV is the causative agent for clinical symptoms.”

Since no quantified virus isolates of the 2019-nCoV are currently available, assays designed for detection of the 2019-nCoV RNA were tested with characterized stocks of in vitro transcribed full length RNA (N gene; GenBank accession: MN908947.2) of known titer (RNA copies/μL) spiked into a diluent consisting of a suspension of human A549 cells and viral transport medium (VTM) to mimic clinical specimen.”

Bud’s comments:  The PCR test has multiple probes designed insilico (i.e. in a computer) from the GenBank sequence database based on the N gene, not from isolated and validated sequence of SARS CoV-2.  The N gene sequence codes for the glycoprotein coating that encapsulates and protects the RNA in the virus from nucleases in the body which would break apart the RNA sequence of the virus. 

The human immune system does not work by recognition of RNA, DNA or protein sequence.  Both T-cells and antibodies function by a 3D pattern recognition of the conformation (or epitope) of the glyco- (i.e. sugar) groups on the surface of the protein.  These sugar groups are post translational modifications to the protein, that is, the sugar groups are added after the protein has been created from amino acids specified in the template of sequence of nucleotides.  Small changes in the RNA and DNA sequence code (as small as a single nucleotide, a SNP) can move a methyl group (-CH3) from one position on the protein to another position on the protein and result in major changes in the 3D surface of the glyco- groups attached to the protein and in the 3D structure of the protein itself.  A small change in RNA sequence or sequence homology can change the ability of a test or the immune system to recognize a virus.  Or, that change may be and likely is a post translational change due to an entirely different, untested protein molecule, e.g. a chaperone, with entirely different sequence not found in the PCR test.  Changes in 3D conformation of the protein can make major changes in the binding function of the S spike protein, or the conformaton of the glycoprotein coating, or other functions of the protein which in turn can result in major changes in infectivity of the virus.  The changes can also prevent or change recognition of the virus by natural or synthetic antibodies, T-cells and pcr tests.      

For example, in this informative recent paper:  “An increasing body of evidence suggests that the tight binding of the S protein to ACE2 is the reason for the high person-to-person transmission rates and severity associated with this disease11,12,45. This is most evident when comparing the SARS 2002–2004 pandemic with the SARS-CoV-2 pandemic, with 8,098 cases versus over 16 million cases (26th July 2020) respectively. Our analysis demonstrated that the SARS-CoV and SARS-CoV-2 S proteins have substantial differences in their ACE2 binding motifs (50% identity), which results in an increased number of contacts between the SARS-CoV-2 S protein and ACE2. This correlates with the observed 10- to 20-fold higher affinity of the SARS-CoV-2 S protein for ACE2, compared to SARS-CoV S protein11.” “…the high level of TMPRSS2 similarity between species does not appear to affect viral entry, but instead it is the species-specific differences in the structure of ACE2 that affects SARS-CoV and SARS-CoV-2 infectivity.”  Brooke GN, Prischi F. Structural and functional modelling of SARS-CoV-2 entry in animal models. Sci Rep. 2020;10(1):15917. Published 2020 Sep 28. doi:10.1038/s41598-020-72528-z.  : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522990/

Recall that the experiments that were underway at the top security U.S. labs, but ruled too dangerous, and were then transferred along with funding to the lab in Wuhan, China were “gain of function” experiments. The function of infectivity is changed by changing the 3D conformation of proteins.  A synthetic sequence created from a computer model could create a protein vaccine for which some people have no immune defense, essentially a poison.   

It bothers me that the world is running millions of PCR tests and antibody tests which have not been validated against the RNA from isolated and filtered SARS CoV-2 virus.  At least, I have not been able to find publication of this information.  The CDC document is very concerning.  And now, without validation against isolated, filtered virus using either standard Koch’s or Rivers’ postulates (methods which have been used to validate cause for every other pandemic including SARS CoV-1 from the 2002-2004 pandemic), vaccines are being created based on synthetic sequence designed to cause invivo human cells in the living, healthy patient to produce one or more proteins from the S-spike protein on the virus, but neither this sequence nor the protein it produces has been validated against the sequence of the S-spike protein on isolated SARS CoV2.  Billions of dollars are being spent on tests and vaccines which have not been validated against actual SARS CoV-2.  Does it bother you?

  1. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel For Emergency Use Only Instructions for Use Catalog # 2019-nCoVEUA-01 1000 reactions For In-vitro Diagnostic (IVD) Use Rx Only.  Division of Viral Diseases / Respiratory Viruses Branch CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel – Verification Requirements *** DO NOT DISCARD: Important product-specific information *** Document #: CDC-006-00005Revision #: 05  https://www.fda.gov/media/134922/download
  2. Brooke GN, Prischi F. Structural and functional modelling of SARS-CoV-2 entry in animal models. Sci Rep. 2020;10(1):15917. Published 2020 Sep 28. doi:10.1038/s41598-020-72528-z.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522990/
  3. Viruses and Koch’s Postulates, Thomas M. Rivers. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545348/
  4. (2) Koch’s postulates fulfilled for SARS virus. Ron A. M. Fouchier, et al. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095368/
  5. (3) Amending Koch’s postulates for viral disease: When “growth in pure culture” leads to a loss of virulence, Joseph Prescott, Heinz Feldmann, and David Safronetz. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5182102/
  6. https://budbromley.blog/2020/08/09/the-covid-cart-is-in-front-of-the-horse/
  7. https://budbromley.blog/2020/08/05/is-cov-2-confirmed-as-the-cause-of-this-pandemic/

About budbromley

Bud is a retired life sciences executive. Bud's entrepreneurial leadership exceeded three decades. He was the senior business development, marketing and sales executive at four public corporations, each company a supplier of analytical and life sciences instrumentation, software, consumables and service. Prior to those positions, his 19 year career in Hewlett-Packard Company's Analytical Products Group included worldwide sales and marketing responsibility for Bioscience Products, Global Accounts and the International Olympic Committee, as well as international management assignments based in Japan and Latin America. Bud has visited and worked in more than 65 countries and lived and worked in 3 countries.
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.